ZVRA vs. EOLS, AUPH, PRAX, WVE, ETNB, NRIX, NUVB, PLRX, STOK, and GHRS
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Evolus (EOLS), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Wave Life Sciences (WVE), 89bio (ETNB), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB), Pliant Therapeutics (PLRX), Stoke Therapeutics (STOK), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Evolus (NASDAQ:EOLS) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
Evolus has a net margin of -27.31% compared to Evolus' net margin of -181.76%. Zevra Therapeutics' return on equity of 0.00% beat Evolus' return on equity.
Evolus received 329 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 72.00% of users gave Evolus an outperform vote.
Evolus has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500.
In the previous week, Evolus and Evolus both had 3 articles in the media. Zevra Therapeutics' average media sentiment score of 1.37 beat Evolus' score of 1.30 indicating that Evolus is being referred to more favorably in the media.
Evolus currently has a consensus price target of $21.25, indicating a potential upside of 64.35%. Zevra Therapeutics has a consensus price target of $19.50, indicating a potential upside of 319.35%. Given Evolus' higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Evolus.
Zevra Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
90.7% of Evolus shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Evolus beats Zevra Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
